Concepts (211)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Muscle, Skeletal | 7 | 2022 | 486 | 1.920 |
Why?
|
Compartment Syndromes | 3 | 2022 | 38 | 1.740 |
Why?
|
Aging | 4 | 2017 | 857 | 1.110 |
Why?
|
Regeneration | 4 | 2016 | 168 | 1.090 |
Why?
|
Induced Pluripotent Stem Cells | 1 | 2022 | 13 | 0.870 |
Why?
|
Cell Differentiation | 5 | 2022 | 430 | 0.850 |
Why?
|
Rats, Inbred Lew | 6 | 2022 | 130 | 0.760 |
Why?
|
Receptors, Transforming Growth Factor beta | 2 | 2008 | 11 | 0.650 |
Why?
|
Proteoglycans | 2 | 2008 | 30 | 0.650 |
Why?
|
Animals | 19 | 2022 | 6402 | 0.650 |
Why?
|
Muscle Fibers, Skeletal | 4 | 2017 | 102 | 0.640 |
Why?
|
Stem Cells | 2 | 2017 | 292 | 0.610 |
Why?
|
Growth Differentiation Factors | 1 | 2016 | 1 | 0.600 |
Why?
|
Tissue Engineering | 5 | 2014 | 607 | 0.600 |
Why?
|
Bone Morphogenetic Proteins | 1 | 2016 | 25 | 0.590 |
Why?
|
Molecular Chaperones | 3 | 2005 | 12 | 0.570 |
Why?
|
Recovery of Function | 2 | 2014 | 174 | 0.560 |
Why?
|
Glycoproteins | 3 | 2005 | 35 | 0.560 |
Why?
|
Disease Models, Animal | 4 | 2016 | 915 | 0.560 |
Why?
|
Rats | 5 | 2022 | 1425 | 0.470 |
Why?
|
Transcription Factors | 2 | 2005 | 175 | 0.460 |
Why?
|
Myoblasts | 3 | 2017 | 38 | 0.440 |
Why?
|
Muscles | 1 | 2012 | 55 | 0.430 |
Why?
|
Neovascularization, Physiologic | 1 | 2012 | 106 | 0.420 |
Why?
|
Mice | 8 | 2022 | 2181 | 0.410 |
Why?
|
Genes, Tumor Suppressor | 2 | 2007 | 36 | 0.380 |
Why?
|
Endothelial Cells | 4 | 2014 | 176 | 0.340 |
Why?
|
Humans | 21 | 2022 | 28304 | 0.320 |
Why?
|
Cell Movement | 1 | 2008 | 157 | 0.310 |
Why?
|
Cadherins | 1 | 2007 | 24 | 0.310 |
Why?
|
Protein-Serine-Threonine Kinases | 1 | 2007 | 42 | 0.310 |
Why?
|
Apoptosis | 4 | 2008 | 333 | 0.310 |
Why?
|
Tumor Suppressor Protein p53 | 3 | 2004 | 67 | 0.300 |
Why?
|
Fibrosis | 2 | 2017 | 112 | 0.300 |
Why?
|
Tissue Scaffolds | 4 | 2014 | 385 | 0.290 |
Why?
|
Mice, Nude | 4 | 2012 | 271 | 0.280 |
Why?
|
DNA Damage | 2 | 2003 | 88 | 0.280 |
Why?
|
Cell Proliferation | 4 | 2017 | 567 | 0.270 |
Why?
|
Breast Neoplasms | 3 | 2009 | 655 | 0.270 |
Why?
|
Receptor, IGF Type 1 | 1 | 2005 | 7 | 0.270 |
Why?
|
Immediate-Early Proteins | 1 | 2005 | 9 | 0.260 |
Why?
|
src-Family Kinases | 1 | 2005 | 15 | 0.260 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2005 | 35 | 0.260 |
Why?
|
MAP Kinase Signaling System | 1 | 2005 | 59 | 0.260 |
Why?
|
DNA-Binding Proteins | 1 | 2005 | 144 | 0.250 |
Why?
|
Repressor Proteins | 1 | 2003 | 52 | 0.230 |
Why?
|
Blood Vessel Prosthesis | 2 | 2014 | 74 | 0.230 |
Why?
|
Gene Expression Regulation | 2 | 2005 | 467 | 0.230 |
Why?
|
Cell Survival | 3 | 2017 | 265 | 0.230 |
Why?
|
Fiber Optic Technology | 2 | 2013 | 13 | 0.230 |
Why?
|
Pituitary Gland | 1 | 2022 | 5 | 0.220 |
Why?
|
Pituitary-Adrenal System | 1 | 2022 | 21 | 0.220 |
Why?
|
Hypothalamo-Hypophyseal System | 1 | 2022 | 27 | 0.220 |
Why?
|
Female | 8 | 2022 | 17679 | 0.220 |
Why?
|
Male | 7 | 2022 | 16967 | 0.210 |
Why?
|
Necrosis | 1 | 2022 | 49 | 0.210 |
Why?
|
Organoids | 1 | 2022 | 67 | 0.200 |
Why?
|
Muscle Development | 2 | 2018 | 45 | 0.200 |
Why?
|
Cell Line, Tumor | 3 | 2008 | 659 | 0.190 |
Why?
|
Radiation, Ionizing | 3 | 2005 | 22 | 0.190 |
Why?
|
Isometric Contraction | 2 | 2017 | 21 | 0.190 |
Why?
|
Fluorescent Dyes | 2 | 2018 | 43 | 0.190 |
Why?
|
Green Fluorescent Proteins | 2 | 2017 | 67 | 0.180 |
Why?
|
Sus scrofa | 3 | 2017 | 44 | 0.180 |
Why?
|
Body Weight | 2 | 2017 | 289 | 0.170 |
Why?
|
Promoter Regions, Genetic | 3 | 2005 | 218 | 0.170 |
Why?
|
Microscopy, Fluorescence | 3 | 2014 | 76 | 0.170 |
Why?
|
Cell Cycle | 2 | 2016 | 68 | 0.160 |
Why?
|
Cell Line | 4 | 2018 | 418 | 0.160 |
Why?
|
Clusterin | 4 | 2006 | 6 | 0.160 |
Why?
|
Neoplasm Invasiveness | 2 | 2009 | 189 | 0.160 |
Why?
|
Fluorescent Antibody Technique | 1 | 2017 | 82 | 0.160 |
Why?
|
Organ Size | 1 | 2017 | 204 | 0.150 |
Why?
|
Myoblasts, Skeletal | 1 | 2016 | 16 | 0.150 |
Why?
|
RNA, Small Interfering | 2 | 2008 | 102 | 0.140 |
Why?
|
Pressure | 2 | 2017 | 54 | 0.140 |
Why?
|
NF-kappa B | 2 | 2008 | 76 | 0.140 |
Why?
|
Urinary Incontinence, Stress | 1 | 2016 | 64 | 0.140 |
Why?
|
Stem Cell Transplantation | 1 | 2017 | 202 | 0.140 |
Why?
|
Urethra | 1 | 2017 | 100 | 0.140 |
Why?
|
Extracellular Matrix | 1 | 2017 | 225 | 0.140 |
Why?
|
Mitochondrial Membranes | 1 | 2014 | 21 | 0.130 |
Why?
|
Endopeptidases | 1 | 2014 | 26 | 0.130 |
Why?
|
Cross-Linking Reagents | 1 | 2014 | 15 | 0.120 |
Why?
|
Age Factors | 2 | 2014 | 1058 | 0.120 |
Why?
|
Mitochondrial Proteins | 1 | 2014 | 68 | 0.120 |
Why?
|
Oxygen Consumption | 1 | 2014 | 138 | 0.120 |
Why?
|
Bioprosthesis | 1 | 2014 | 55 | 0.120 |
Why?
|
Energy Metabolism | 1 | 2014 | 139 | 0.120 |
Why?
|
Mice, Transgenic | 2 | 2016 | 221 | 0.120 |
Why?
|
Endothelium, Corneal | 1 | 2013 | 22 | 0.110 |
Why?
|
Implants, Experimental | 1 | 2012 | 12 | 0.110 |
Why?
|
Mitochondria | 1 | 2014 | 175 | 0.110 |
Why?
|
Radiation | 1 | 2012 | 1 | 0.110 |
Why?
|
Coculture Techniques | 1 | 2012 | 74 | 0.110 |
Why?
|
Mass Media | 1 | 2012 | 12 | 0.110 |
Why?
|
Prosthesis Implantation | 1 | 2012 | 35 | 0.110 |
Why?
|
Muscular Diseases | 1 | 2012 | 19 | 0.110 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2012 | 101 | 0.110 |
Why?
|
Endothelium, Vascular | 1 | 2013 | 149 | 0.110 |
Why?
|
Mutation | 1 | 2014 | 451 | 0.110 |
Why?
|
Desmin | 1 | 2011 | 12 | 0.110 |
Why?
|
Myositis | 1 | 2011 | 10 | 0.110 |
Why?
|
Research | 1 | 2012 | 67 | 0.110 |
Why?
|
Edema | 1 | 2011 | 30 | 0.110 |
Why?
|
Carotid Arteries | 1 | 2012 | 103 | 0.100 |
Why?
|
Ligation | 1 | 2011 | 55 | 0.100 |
Why?
|
Cells, Cultured | 4 | 2017 | 779 | 0.100 |
Why?
|
Quality of Life | 1 | 2016 | 792 | 0.100 |
Why?
|
Muscle Strength | 1 | 2011 | 123 | 0.100 |
Why?
|
Wound Healing | 1 | 2012 | 180 | 0.100 |
Why?
|
Neoplasms | 3 | 2006 | 596 | 0.100 |
Why?
|
Phospholipase D | 1 | 2009 | 5 | 0.090 |
Why?
|
Isoenzymes | 1 | 2009 | 59 | 0.090 |
Why?
|
Transforming Growth Factor beta2 | 1 | 2008 | 6 | 0.090 |
Why?
|
Mammary Neoplasms, Experimental | 1 | 2008 | 25 | 0.080 |
Why?
|
Transplantation, Heterologous | 1 | 2008 | 120 | 0.080 |
Why?
|
Enzyme Inhibitors | 1 | 2009 | 147 | 0.080 |
Why?
|
Up-Regulation | 1 | 2008 | 180 | 0.080 |
Why?
|
Signal Transduction | 2 | 2008 | 607 | 0.080 |
Why?
|
RNA, Untranslated | 1 | 2007 | 10 | 0.080 |
Why?
|
Mammary Glands, Human | 1 | 2007 | 15 | 0.080 |
Why?
|
RNA Interference | 1 | 2007 | 71 | 0.080 |
Why?
|
Cell Physiological Phenomena | 1 | 2006 | 3 | 0.080 |
Why?
|
Feedback, Physiological | 1 | 2006 | 9 | 0.080 |
Why?
|
Down-Regulation | 1 | 2007 | 138 | 0.080 |
Why?
|
Epithelial Cells | 1 | 2007 | 139 | 0.070 |
Why?
|
Primates | 2 | 2017 | 70 | 0.070 |
Why?
|
Transforming Growth Factor beta | 1 | 2006 | 65 | 0.070 |
Why?
|
Early Growth Response Protein 1 | 1 | 2005 | 4 | 0.070 |
Why?
|
Genomic Instability | 1 | 2004 | 3 | 0.070 |
Why?
|
Bystander Effect | 1 | 2004 | 6 | 0.070 |
Why?
|
PAX7 Transcription Factor | 2 | 2016 | 8 | 0.070 |
Why?
|
Enzyme Activation | 1 | 2005 | 120 | 0.060 |
Why?
|
Radiation Tolerance | 1 | 2004 | 22 | 0.060 |
Why?
|
Lung Neoplasms | 1 | 2008 | 374 | 0.060 |
Why?
|
Oncogene Proteins, Viral | 1 | 2003 | 1 | 0.060 |
Why?
|
Complement Inactivator Proteins | 1 | 2003 | 2 | 0.060 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2003 | 6 | 0.060 |
Why?
|
Cyclins | 1 | 2003 | 5 | 0.060 |
Why?
|
Cytoplasm | 1 | 2003 | 29 | 0.060 |
Why?
|
Gamma Rays | 1 | 2003 | 24 | 0.060 |
Why?
|
Colonic Neoplasms | 1 | 2003 | 63 | 0.060 |
Why?
|
Transcription, Genetic | 1 | 2003 | 138 | 0.060 |
Why?
|
Optics and Photonics | 2 | 2012 | 7 | 0.060 |
Why?
|
Microcirculation | 2 | 2012 | 61 | 0.050 |
Why?
|
Neoplasm Proteins | 1 | 2003 | 143 | 0.050 |
Why?
|
Antineoplastic Agents | 2 | 2006 | 532 | 0.050 |
Why?
|
Bioreactors | 2 | 2012 | 59 | 0.050 |
Why?
|
Equipment Design | 2 | 2012 | 161 | 0.050 |
Why?
|
RNA, Messenger | 1 | 2003 | 498 | 0.050 |
Why?
|
Prostatic Neoplasms | 1 | 2003 | 438 | 0.040 |
Why?
|
Myogenic Regulatory Factor 5 | 1 | 2018 | 7 | 0.040 |
Why?
|
Transforming Growth Factor alpha | 1 | 2018 | 3 | 0.040 |
Why?
|
Wnt Proteins | 1 | 2018 | 18 | 0.040 |
Why?
|
Cell Count | 1 | 2017 | 48 | 0.040 |
Why?
|
Organ Specificity | 1 | 2017 | 77 | 0.040 |
Why?
|
Hyaluronic Acid | 1 | 2017 | 44 | 0.040 |
Why?
|
Gluconates | 1 | 2016 | 2 | 0.040 |
Why?
|
Ouabain | 1 | 2016 | 5 | 0.040 |
Why?
|
Heparin | 1 | 2017 | 73 | 0.040 |
Why?
|
Potassium | 1 | 2016 | 36 | 0.040 |
Why?
|
Membrane Potentials | 1 | 2016 | 63 | 0.040 |
Why?
|
Injections, Intravenous | 1 | 2016 | 56 | 0.040 |
Why?
|
Social Behavior | 1 | 2017 | 58 | 0.040 |
Why?
|
Flow Cytometry | 1 | 2017 | 169 | 0.040 |
Why?
|
Blotting, Western | 1 | 2016 | 265 | 0.040 |
Why?
|
DNA | 1 | 2017 | 207 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2016 | 436 | 0.030 |
Why?
|
Collagen | 1 | 2017 | 221 | 0.030 |
Why?
|
Macaca fascicularis | 1 | 2016 | 330 | 0.030 |
Why?
|
Immunohistochemistry | 1 | 2016 | 515 | 0.030 |
Why?
|
Mice, Inbred C57BL | 1 | 2016 | 619 | 0.030 |
Why?
|
Mice, Mutant Strains | 1 | 2014 | 44 | 0.030 |
Why?
|
Biomedical Engineering | 1 | 2013 | 23 | 0.030 |
Why?
|
Collagen Type IV | 1 | 2013 | 8 | 0.030 |
Why?
|
Collagenases | 1 | 2013 | 9 | 0.030 |
Why?
|
Culture Media | 1 | 2013 | 38 | 0.030 |
Why?
|
Fibronectins | 1 | 2013 | 32 | 0.030 |
Why?
|
Polyesters | 1 | 2013 | 70 | 0.030 |
Why?
|
Silicon Dioxide | 1 | 2012 | 8 | 0.030 |
Why?
|
Photons | 1 | 2012 | 7 | 0.030 |
Why?
|
Electrons | 1 | 2012 | 11 | 0.030 |
Why?
|
Cell Shape | 1 | 2012 | 26 | 0.030 |
Why?
|
Microspheres | 1 | 2012 | 37 | 0.030 |
Why?
|
Light | 1 | 2012 | 25 | 0.030 |
Why?
|
Microscopy, Confocal | 1 | 2012 | 56 | 0.030 |
Why?
|
Phantoms, Imaging | 1 | 2012 | 56 | 0.030 |
Why?
|
Swine | 1 | 2012 | 198 | 0.030 |
Why?
|
Time Factors | 1 | 2016 | 1874 | 0.030 |
Why?
|
Odds Ratio | 1 | 2013 | 457 | 0.030 |
Why?
|
Interviews as Topic | 1 | 2012 | 240 | 0.030 |
Why?
|
Cell Culture Techniques | 1 | 2012 | 161 | 0.030 |
Why?
|
Models, Statistical | 1 | 2012 | 157 | 0.030 |
Why?
|
Sex Factors | 1 | 2013 | 619 | 0.020 |
Why?
|
Urinary Bladder | 1 | 2012 | 163 | 0.020 |
Why?
|
Skin | 1 | 2012 | 200 | 0.020 |
Why?
|
Treatment Outcome | 1 | 2017 | 2886 | 0.020 |
Why?
|
Drug Design | 1 | 2009 | 41 | 0.020 |
Why?
|
Naphthoquinones | 1 | 2006 | 3 | 0.020 |
Why?
|
DNA Mismatch Repair | 1 | 2006 | 4 | 0.020 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2006 | 15 | 0.020 |
Why?
|
Cell Death | 1 | 2006 | 66 | 0.020 |
Why?
|
Ligands | 1 | 2006 | 59 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2006 | 192 | 0.020 |
Why?
|
Protein Isoforms | 1 | 2004 | 50 | 0.020 |
Why?
|
Models, Biological | 1 | 2006 | 356 | 0.020 |
Why?
|
Proteins | 1 | 2004 | 142 | 0.010 |
Why?
|
Adult | 1 | 2013 | 8243 | 0.010 |
Why?
|
Aged | 1 | 2013 | 9256 | 0.010 |
Why?
|
Middle Aged | 1 | 2013 | 10678 | 0.010 |
Why?
|